Omnicell (NASDAQ:OMCL - Get Free Report) updated its second quarter 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.100-0.200 for the period, compared to the consensus estimate of 0.270. The company issued revenue guidance of $250.0 million-$260.0 million, compared to the consensus revenue estimate of $261.9 million. Omnicell also updated its FY 2024 guidance to 0.900-1.400 EPS.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the company. Benchmark reiterated a buy rating and set a $38.00 price objective on shares of Omnicell in a research note on Tuesday. Wells Fargo & Company lowered their price target on shares of Omnicell from $28.00 to $26.00 and set an equal weight rating on the stock in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and an average target price of $42.20.
Check Out Our Latest Stock Report on Omnicell
Omnicell Trading Up 2.9 %
OMCL stock traded up $0.84 during trading on Friday, reaching $30.13. The company had a trading volume of 865,887 shares, compared to its average volume of 540,387. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.52 and a quick ratio of 2.22. Omnicell has a 52 week low of $25.69 and a 52 week high of $77.14. The business has a 50 day moving average of $27.73 and a 200 day moving average of $31.80. The company has a market cap of $1.38 billion, a P/E ratio of -66.96 and a beta of 0.77.
Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The company had revenue of $258.85 million for the quarter, compared to analysts' expectations of $256.00 million. As a group, sell-side analysts forecast that Omnicell will post 0.09 earnings per share for the current fiscal year.
Omnicell Company Profile
(
Get Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
Recommended Stories
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
